iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, and Breastlink Medical Group in Southern California, today announced an agreement that will make the Xoft® Axxent® Electronic Brachytherapy System® available to breast cancer patients treated at Breastlink. The Xoft system for Intraoperative Radiation Therapy (IORT) delivers a single, prescribed, targeted dose of radiation during surgery directly to the tumor cavity - minimizing radiation to healthy tissue and organs. The announcement was made during the annual meeting of the American Society of Breast Surgeons, in Phoenix, where iCAD is showcasing the Xoft system. Breastlink Medical Group is affiliated with RadNet Management, Inc., which manages a network of outpatient imaging and comprehensive cancer treatment centers.
"By adopting the Xoft system for IORT at our practice, we are providing select patients with a treatment option that lets them receive a full course of radiation therapy during their lumpectomy procedure, eliminating the emotional and physical burden of traditional radiation therapy which can require weeks of daily treatments," said Amy Bremner, MD, breast surgeon at Breastlink Medical Group. "At Breastlink we are committed to providing our patients with cutting-edge treatment options like the Xoft system that provide optimal care and get our patients back to their active lifestyles as quickly as possible."
"Breast surgeons and radiation oncologists looking to offer their patients advanced radiation therapy treatment options that can be delivered in shorter timeframes while minimizing radiation exposure continue to select the Xoft system for Intraoperative Radiation Therapy," said Ken Ferry, President and CEO of iCAD. "The availability of the Xoft system by Breastlink Medical Group demonstrates the continued adoption of this innovative treatment by leading breast health centers in the U.S."
As the Xoft system does not require a shielded environment and is relatively small in size, it can easily be transported for use in virtually any clinical setting (including the operating room where IORT is delivered) under radiation oncology supervision. The Xoft system may also be used for accelerated partial breast irradiation (APBI), which can be delivered twice daily for five days.
The Xoft system is cleared by the U.S. Food and Drug Administration for the treatment of conditions where radiation is indicated, including early stage breast cancer, skin cancer, and endometrial cancer.
Study reveals vascular health disparities between Black and white men with prostate cancer diagnosis